This website uses cookies to improve your experience. To learn more about information collected on our website read our Cookie Notice here
Our Story

Driven to Do More

Every day, we come to work focused and driven by the opportunity to deliver the next best-in-class therapy for patients with genetically defined diseases – to move beyond incremental improvements and solely treating symptoms, to address the real causes of disease. We are methodical, rational, and intentional in our approach to identify pragmatic solutions to complex health challenges with the goal of restoring health and allowing patients to live better, longer lives.

Our Mission

To design rational precision therapies that treat the underlying cause of disease to improve patients’ lives.

Our Vision

To discover, develop, and commercialize best-in-class therapies that have a dramatic impact for patients with genetically defined diseases.

Leadership

Andrew Robbins
CEO and President of Cogent Biosciences
Jessica Sachs, MD
Chief Medical Officer
John Robinson, PhD
Chief Scientific Officer
Brad Barnett
Chief Technology Officer
Erin Schellhammer
Chief People Officer
Evan Kearns, JD
Chief Legal Officer and Corporate Secretary
John Green
Chief Financial Officer
Sara Saltzman
Senior Vice President, Regulatory Affairs
Dana Martin, PharmD
Senior Vice President, Medical Affairs & Chief Patient Officer
Zamaneh Mikhak, MD
Senior Vice President, Head of Clinical Development 
Sara Saltzman
SVP, Regulatory Affairs
Dana Martin, PharmD
Senior Vice President, Medical Affairs & Chief Patient Officer
Andrew Robbins
CEO and President of Cogent Biosciences
Jessica Sachs, MD
Chief Medical Officer
Jessica Sachs, MD
Chief Medical Officer
John Robinson, PhD
Chief Scientific Officer
Brad Barnett
Chief Technology Officer
Erin Schellhammer
Chief People Officer
Evan Kearns, JD
Chief Legal Officer and Corporate Secretary
John Green
Chief Financial Officer
Sara Saltzman
SVP, Regulatory Affairs
Dana Martin, PharmD
Senior Vice President, Medical Affairs & Chief Patient Officer

Board of Directors

Peter Harwin
Managing Member, Fairmount Funds Management LLC
Chris Cain
Director of Research, Fairmount Funds Management LLC
Karen Ferrante
Medical Oncologist and former Pharma-Biotech Executive
Arlene M. Morris
Chief Executive Officer, Willow Advisors
Matthew E. Ros
Bio-Pharmaceutical Executive
Todd E. Shegog
Chief Financial Officer, Forma Therapeutics 
Andrew Robbins
CEO and President of Cogent Biosciences
Dana Martin, PharmD
Senior Vice President, Medical Affairs & Chief Patient Officer
Peter Harwin
Managing Member, Fairmount Funds Management LLC
Jessica Sachs, MD
Chief Medical Officer
Chris Cain
Director of Research, Fairmount Funds Management LLC
Karen Ferrante
Medical Oncologist and former Pharma-Biotech Executive
Arlene M. Morris
Chief Executive Officer, Willow Advisors
Matthew E. Ros
Bio-Pharmaceutical Executive
Todd E. Shegog
Chief Financial Officer, Forma Therapeutics
Andrew Robbins
CEO and President of Cogent Biosciences

Research Leadership

John Robinson, PhD
Chief Scientific Officer
Brad Fell
VP, Head of Medicinal Chemistry
Francis Sullivan, PhD
VP, Enzymology and Structural Biology
Shannon Winski, PhD
VP, Pharmacology and Toxicology
John Robinson, PhD
Chief Scientific Officer
Jessica Sachs, MD
Chief Medical Officer
Brad Fell
VP, Head of Medicinal Chemistry
Francis Sullivan, PhD
VP, Enzymology and Structural Biology
Shannon Winski, PhD
VP, Pharmacology and Toxicology

Scientific Advisory Board

NYU Langone Health
Srdan Verstovsek, MD, PhD
Anderson Cancer Center
Michael Vasconcelles, MD
Chief Medical Officer, Flatiron Health
Ryan Corcoran, MD, PhD
Massachusetts General Hospital Cancer Center
Kwok-Kin Wong, MD, PhD
NYU Langone Health
Jessica Sachs, MD
Chief Medical Officer
Srdan Verstovsek, MD, PhD
Head of Medicinal Chemistry
Michael Vasconcelles, MD
Chief Medical Officer, Flatiron Health
Ryan Corcoran, MD, PhD
Massachusetts General Hospital Cancer Center
Andrew Robbins
Chief Executive Officer & President

The Cogent team is driven to discover and develop novel precision medicines. Beginning with bezuclastinib, we strive to improve the lives of patients fighting rare, genetically driven diseases.